Skip to main content
. 2015 Dec 22;10(5):693–703. doi: 10.1016/j.molonc.2015.12.010

Figure 1.

Figure 1

A, Analytical strategy employed for this study. 21 out of 396 differentially expressed snoRNAs (Met. vs. Non‐met. xenografts) were searched in the MSKCC database containing 267 snoRNAs. 12/21 genes were also represented in this platform and were chosen for further analyses. The gene(s) associated with PCa prognosis were validated in an independent clinical dataset. B, Relapse‐free survival according to SNORA55 expression in primary tumor at diagnosis, (MSKCC database, dichotomization based on Z score, as described in “Methods”) *p < 0.05 (log rank test, Bonferroni correction). C, SNORA55 expression measured by qPCR in 9 BPH and 43 primary PCa samples. **p < 0.01 (unpaired T test). D, Relapse‐free survival according to SNORA55 expression in primary tumor at diagnosis (qPCR on 43 samples). **p < 0.01 (log rank test). E, Expression of SNORA55 in serum samples from PCa patients and healthy controls. *p < 0.05 (unpaired, two‐sided T test).